Deoxyhypusine Synthase-mediated Hypusination of eIF5A Drives PASMC Proliferation and Vascular Remodeling in Pulmonary Arterial Hypertension

Autor: S.-E. Lemay, Y. Grobs, S. Martineau, M. Salem, T. Shimauchi, S. Breuils-Bonnet, A. Bourgeois, F. Potus, S. Provencher, S. Bonnet, O. Boucherat

Publikováno v: D18. MOLECULAR TRAFFIC HUBS IN PULMONARY VASCULAR DISEASE.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::68e9640f25ef6c5c83068c332bcec910
https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6249

Targeting Integrins Signaling: A Novel Therapeutic Avenue to Counter Vascular Remodeling and Right Ventricular Failure in Pulmonary Arterial Hypertension

Autor: S.-E. Lemay, M. Montesinos, Y. Grobs, T. Yokokawa, T. Shimauchi, S. Breuils Bonnet, S. Martineau, M. Orcholski, A. Bourgeois, C. Romanet, X. Huang, J.E. Dowling, M. Lu, A.S. Ray, F. Potus, S. Provencher, O. Boucherat, S. Bonnet

Publikováno v: B96. FISHERMAN'S WHARF: OMICS AND TRANSLATIONAL APPROACHES IN PULMONARY VASCULAR DISEASE.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c53032704a84374367a0c6d9bfdebe8a
https://doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3443

The AKT/FOXO3 Axis Involvement in Pulmonary Arterial Hypertension Development

Autor: Y. Grobs, C. romanet, J. Omura, V. Nadeau, M. Orcholski, T. Shimauchi, V. Toro, E. Tremblay, S.-E. Lemay, A. Bourgeois, R. Paulin, S. Provencher, O. Boucherat, S. Bonnet

Publikováno v: TP85. TP085 A HARD DAY?S NIGHT - NOVEL MOLECULAR MECHANISMS AND TREATMENT OPTIONS IN PAH AND BEYOND: FROM PULMONARY VASCULATURE TO RV.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7da8a04589f494ce2f37833632232adf
https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3651

Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical Studies.

Autor: Lemay SE; Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.)., Montesinos MS; Morphic Therapeutic, Inc, Waltham, MA (M.S.M., M.A., A.S.R., B.L., B.G., F.-Y.L., H.W., J.E.D., M.L., Q.Q., T.A.M., T.I.M.)., Grobs Y; Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.)., Yokokawa T; Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.).; Department of Cardiovascular Medicine, Fukushima Medical University, Japan (T.Y.)., Shimauchi T; Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.).; Department of Anesthesiology, St Mary's Hospital, Kurume, Fukuoka, Japan (T.S.)., Mougin M; Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.)., Romanet C; Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.)., Sauvaget M; Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.)., Breuils-Bonnet S; Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.)., Bourgeois A; Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.)., Théberge C; Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.)., Pelletier A; Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.)., El Kabbout R; Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.)., Martineau S; Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.)., Yamamoto K; Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.)., Akram M; Morphic Therapeutic, Inc, Waltham, MA (M.S.M., M.A., A.S.R., B.L., B.G., F.-Y.L., H.W., J.E.D., M.L., Q.Q., T.A.M., T.I.M.)., Ray AS; Morphic Therapeutic, Inc, Waltham, MA (M.S.M., M.A., A.S.R., B.L., B.G., F.-Y.L., H.W., J.E.D., M.L., Q.Q., T.A.M., T.I.M.)., Lippa B; Morphic Therapeutic, Inc, Waltham, MA (M.S.M., M.A., A.S.R., B.L., B.G., F.-Y.L., H.W., J.E.D., M.L., Q.Q., T.A.M., T.I.M.)., Goodwin B; Morphic Therapeutic, Inc, Waltham, MA (M.S.M., M.A., A.S.R., B.L., B.G., F.-Y.L., H.W., J.E.D., M.L., Q.Q., T.A.M., T.I.M.)., Lin FY; Morphic Therapeutic, Inc, Waltham, MA (M.S.M., M.A., A.S.R., B.L., B.G., F.-Y.L., H.W., J.E.D., M.L., Q.Q., T.A.M., T.I.M.)., Wang H; Morphic Therapeutic, Inc, Waltham, MA (M.S.M., M.A., A.S.R., B.L., B.G., F.-Y.L., H.W., J.E.D., M.L., Q.Q., T.A.M., T.I.M.)., Dowling JE; Morphic Therapeutic, Inc, Waltham, MA (M.S.M., M.A., A.S.R., B.L., B.G., F.-Y.L., H.W., J.E.D., M.L., Q.Q., T.A.M., T.I.M.)., Lu M; Morphic Therapeutic, Inc, Waltham, MA (M.S.M., M.A., A.S.R., B.L., B.G., F.-Y.L., H.W., J.E.D., M.L., Q.Q., T.A.M., T.I.M.)., Qiao Q; Morphic Therapeutic, Inc, Waltham, MA (M.S.M., M.A., A.S.R., B.L., B.G., F.-Y.L., H.W., J.E.D., M.L., Q.Q., T.A.M., T.I.M.)., McTeague TA; Morphic Therapeutic, Inc, Waltham, MA (M.S.M., M.A., A.S.R., B.L., B.G., F.-Y.L., H.W., J.E.D., M.L., Q.Q., T.A.M., T.I.M.)., Moy TI; Morphic Therapeutic, Inc, Waltham, MA (M.S.M., M.A., A.S.R., B.L., B.G., F.-Y.L., H.W., J.E.D., M.L., Q.Q., T.A.M., T.I.M.)., Potus F; Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.).; Department of Medicine, Laval University, Quebec City, QC, Canada (F.P., S.P., O.B., S.B.)., Provencher S; Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.).; Department of Medicine, Laval University, Quebec City, QC, Canada (F.P., S.P., O.B., S.B.)., Boucherat O; Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.).; Department of Medicine, Laval University, Quebec City, QC, Canada (F.P., S.P., O.B., S.B.)., Bonnet S; Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.).; Department of Medicine, Laval University, Quebec City, QC, Canada (F.P., S.P., O.B., S.B.).

Publikováno v: Circulation [Circulation] 2025 Jan 20. Date of Electronic Publication: 2025 Jan 20.

From Data Mining to Discovery: SNHG11 as a Therapeutic Target in Pulmonary Hypertension.

Autor: Grobs Y; Centre de recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Pneumologie, Québec, Quebec, Canada., Potus F; Pulmonary Hypertension Research Group, Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Quebec, Quebec, Canada; francois.potus.1@ulaval.ca.

Publikováno v: American journal of respiratory cell and molecular biology [Am J Respir Cell Mol Biol] 2024 Sep 17. Date of Electronic Publication: 2024 Sep 17.